Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Uncontrolled hypertension remains a problem
The primary reason for treating hypertension is to reduce the risk for cardiovascular (CV) adverse outcomes while achieving guideline recommended goal blood pressure (BP), which usually requires multiple medications from different antihypertensive classes. Yet epidemiologic data indicate that fewer than 50% of patients achieve guideline recommended goals so associated morbidity and mortality remains high. The relative contributions to lack of BP control and elevated outcome rate among inadequacies of a particular antihypertensive regimen (agent or class), physician inertia with dose titration or drug addition and patient non-adherence with a prescribed drug regimen and life style modifications, are unclear.
Observational study attempts to determine best antihypertensive drug combo
To address the first possibility, Boger-Megiddo and colleagues suggest there may be outcome differences based on antihypertensive regimen employed. The study utilised a case (n=353) control (n=952) design to assess outcomes in a low risk hypertensive population in a managed care setting. The investigators focused on antihypertensive regimens led by a diuretic (usually a thiazides diuretic) with either a β blocker, renin angiotensin system blocker or calcium antagonist …
Funding CJP has received research grants Abbott Laboratories, the National Institutes of Health, Baxter, Pfizer, GlaxoSmithKline and Bioheart; is a consultant to Abbott Laboratories, Forest Labs, Novartis/Cleveland Clinic, NicOx, Angioblast, Sanofi-Aventis, Medtelligence and SLACK; and has received unrestricted educational grants from AstraZeneca, AtCor Medical, Daiichi Sankyo, Eli Lilly, Pfizer, Sanofi-Aventis and Schering-Plough.
Competing interests RCD has been received grant funding from Abbott Laboratories and the National Institutes of Health.